🇺🇸 FDA
Patent

US 12102646

Compositions for the treatment of fibrosis and inflammation

granted A61KA61K31/167A61K31/198

Quick answer

US patent 12102646 (Compositions for the treatment of fibrosis and inflammation) held by Viking Therapeutics, Inc. expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Viking Therapeutics, Inc.
Grant date
Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/167, A61K31/198, A61K31/222, A61K31/404